Physician profile
Tonya Hall
NPI 1104813724
$9,530.42
in general payments reported to CMS, 2019-2025
35 companies · $1,695 in 2025
The $1,695 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,588 · 2020: $294 · 2021: $1,139 · 2022: $1,297 · 2023: $2,007 · 2024: $1,511 · 2025: $1,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,212.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,255.73 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,278.93 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,041.41 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $875.57 | 2019-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $714.22 | 2019-2025 | Epclusa, Livdelzi |
| Phathom Pharmaceuticals, INC. | $549.53 | 2023-2025 | Voquezna |
| Pfizer INC. | $389.83 | 2019-2025 | |
| Ardelyx, INC. | $286.76 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $245.44 | 2021-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $206.98 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $185.69 | 2019-2024 | Linzess |
| Celgene Corporation | $182.11 | 2022-2024 | Zeposia |
| Ucb, INC. | $153.52 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $137.93 | 2019-2024 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $119.98 | 2023-2025 | Dupixent |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $83.39 | 2022 | |
| Genzyme Corporation | $80.13 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $72.76 | 2019 | |
| Allergan, INC. | $69.45 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $69.12 | 2023 | |
| Qol Medical, LLC | $60.81 | 2025 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $57.84 | 2024 | Bylvay |
| Lilly USA, LLC | $56.66 | 2024 | Omvoh |
| Shionogi INC | $52.36 | 2019 | |
| Braintree Laboratories, INC. | $46.44 | 2019-2023 | Sutab |
| Evoke Pharma, INC. | $44.03 | 2023-2024 | Gimoti |
| Alnylam Pharmaceuticals INC. | $41.16 | 2022-2023 | Givlaari |
| Aimmune Therapeutics, INC. | $34.88 | 2025 | Zenpep |
| Fresenius Kabi USA, LLC | $34.52 | 2024 | Idacio |
| Shire North American Group INC | $30.10 | 2019 | |
| Amgen INC. | $22.39 | 2025 | Uplizna |
| Astrazeneca Pharmaceuticals LP | $19.07 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.10 | 2023 | Cyltezo |
| Bausch & Lomb Americas INC. | $13.58 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tonya Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.